Acorda On Track To File Oral MS Therapy Fampridine-SR By Q1 2009
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Acorda Therapeutics intends to file an NDA for its oral multiple sclerosis therapy Fampridine-SR in the first quarter of 2009, CEO Ron Cohen said during a Jan. 28 conference call to report cardiac study results for the drug